Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
50% from low
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2013 | 2014 | 2015 | 2016 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$7.4K | −$24.5K | −$288.9K | −$3.6M | −$1.0M | −$991.6K | −$1.3M | −$554.5K |
| EBITDA | −$7.4K | −$284.7K | −$3.6K | −$3.8M | −$1.0M | −$991.6K | $377.9K | −$2.0M |
| Net income | −$7.4K | −$24.5K | −$288.9K | −$3.6M | −$1.0M | −$991.6K | $141.3K | −$2.3M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.00 | -0.00 | -0.00 | -0.01 | -0.00 | -0.00 | 0.00 | -0.01 |
Annual figures · source: Financial Modeling Prep
MOBILE LADS CORP
No one on the platform currently holds MOBO.
No tracked institution reports a position in MOBO as of their last filing.
| Execution date | Ratio |
|---|---|
| 2014-03-31 | 55-for-1 |
No one on the platform has traded MOBO yet.
| $12892 |
| — |
| EHOSEhouse Global, Inc. | $0.00 | +0.00% | $10127 | — |
| PBLAPanbela Therapeutics, Inc. | $0.01 | +0.00% | $24274 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$MOB Should be a nice bump re $PDYN US airforce contract … tech may include $MOBO OS3 tech.
View on StockTwits ↗$KSCP RoBoT SeCuRiTY🤖 NeXT RuNNeR?!! $QBTS 🖥️ $RGT 💻 $MOBO 🐂DD'EmALL✅ 🐻¥🔨 👀 🏆🐄.. 🎵 STaYiN'-aLiVe 🎶 https://youtu.be/oVCtJvLZvis
View on StockTwits ↗$MOBO ... This chart demonstrates what can happen. What can happen when things get overdone on the downside = Trading opportunities present themselves ! https://www.tradingview.com/x/BI7wlW4s/
View on StockTwits ↗$MOBO Announce we have finalized and signed with North Star Leasing to provide up to $25,000,000.00 of equipment financing for our clients. This facility allows our customers to finance the purchase of our EEG FDA approved medical headsets. The average cost of the EEG headsets is over $30k. North Star Leasing facility will reduce our sales cycle from weeks to days. Allowing us to achieve our $6,000,000.00 in revenue goals. https://finance.yahoo.com/news/north-star-leasing-avail-scientific-145500551.html
View on StockTwits ↗$MOBO $PEBO North Star Leasing and Avail Scientific Have Arranged a $25 Million Dollar Lease Finance Facility https://www.stocktitan.net/news/MOBO/north-star-leasing-and-avail-scientific-have-arranged-a-25-million-nepx1zjmqqkz.html
View on StockTwits ↗$MOBO [15s. delayed]: Issued Press Release on February 23, 09:55:00: North Star Leasing and Avail Scientific Have Arranged a $25 Million D https://s.flashalert.me/6Q9kj
View on StockTwits ↗$MOBO We are focused on South Florida's substance abuse rehabilitation industry which generates over a billion in revenues annually. - As a result, we anticipate rapid growth in our Florida network of clinics in 2023. - Avail Scientific is positioned to capture 5-7% of the rehabilitation market generating $6,000,000 in revenues annually, with each patient requiring a minimum of two EEG reports with a cost of about $500 per report. - There are 3,500 patients being treated as in-patients at programs in Palm Beach, Broward and Miami-Dade countries in southern Florida (Nov 2022), with 20.4 million people aged 12 and older diagnosed with substance use disorder. https://www.accesswire.com/739482/Avail-Scientific-Expecting-Exponential-Annual-Growth-of-6-million-within-Florida-Rehab-Clinics-says-Gerard-Maynard-Chief-Revenue-Officer-for-Avail-Scientific
View on StockTwits ↗$MOBO [15s. delayed]: Issued Press Release on February 15, 11:20:00: "Avail Scientific Expecting Exponential Annual Growth of $6 million w https://s.flashalert.me/HC69L
View on StockTwits ↗$MOBO "Avail Scientific Expecting Exponential Annual Growth of $6 million within Florida Rehab Clinics!" says Gerard Maynard, Chief Revenue Officer for Avail Scientific https://www.stocktitan.net/news/MOBO/avail-scientific-expecting-exponential-annual-growth-of-6-million-uzo655d4vkud.html
View on StockTwits ↗$MOBO subsidiary, Relai Neuro has been selected as an official vendor for the State of Florida, Justice Administrative Commission (JAC) to provide electroencephalograms (EEG's), reports, and services. The JAC has an annual budget of $1.07 Billion. https://finance.yahoo.com/news/relai-neuro-selected-official-vendor-115000171.html
View on StockTwits ↗$MOBO What are “Psychedelics”, such as Psilocybin? Psilocybin is a compound found in many species of mushrooms that creates psychoactive and psychedelic effects, which may include alterations in sensation, cognition, and emotion. Avail uses organically grown mushroom material for our clinical research.
View on StockTwits ↗$MOBO At Avail, we understand the integration of psychedelic therapies into the global health care systems is multifocal and complex. Our dynamic team is composed of diverse experts, each selected to maximize our potential and achieve our common goal. Avail’s data acquisition team are working in conjunction with Brainet, and our proprietary biometric monitoring platform to create a data driven system to develop and perfect therapeutic practices to treat addiction and mental health issues.
View on StockTwits ↗$MOBO Our cultivation partner, Whitecrest, has spent decades mastering the art of mushroom cultivation by integrating new technology with conventional agricultural wisdom. They have created a modular system that uses patented techniques to grow organic, high-quality mushrooms, reduce their carbon footprint and lead the industry in green agricultural practices.
View on StockTwits ↗$MOBO Our R&D team is led by Ccrest and is focusing on the development of new analogs and simplifying the ingestion of certain psychedelic compounds. By streamlining the administration and absorption process, we can make these more accessible to researchers and health care practitioners globally. This will facilitate greater efficiency during research and the treatment process.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.